Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 46

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 46
---
,531 shares of common stock (assuming full exercise of the Common Warrants and the Placement Agent Warrants that are exercisable for the shares of common stock being offered in this prospectus)                                                                                                                                                                                                                                                                                                                                                                           |
| Use of Proceeds                                            |     | We will not receive any proceeds from the sale of the shares of common stock by the Selling Stockholders in the offering described in this prospectus. However, we will receive aggregate proceeds of up to approximately (i) $1,575,229 from the cash exercise of the January 2025 Common Warrants; (ii) $887,065 from the cash exercise of the February 2025 Common Warrants; (iii) $97,785 from the cash exercise of the January 2025 Placement Agent Warrants; and (iv) $100,788 from the cash exercise of the February 2025 Placement Agent Warrants. See “Use of Proceeds.” |
| Listing Symbol                                             |     | Our shares of common stock are listed on The Nasdaq Capital Market under the symbol “SXTP.”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Dividend Policy                                            |     | We have never declared or paid any cash dividends on our shares of common stock. We do not anticipate paying any cash dividends in the foreseeable future.                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Transfer Agent                                             |     | Equity Stock Transfer, LLC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Risk Factors                                               |     | You should carefully consider the information set forth in this prospectus and, in particular, the specific factors set forth in the “Risk Factors” section beginning on page 26 of this prospectus before deciding whether or not to invest in shares of our common stock.                                                                                                                                                                                                                                                                                                       |

| (1) | The number of shares of                                                                                                             
 common stock to be outstanding after this offering is based on 7,364,554 shares of Common Stock outstanding as of February 14, 2025 
 and excludes:                                                                                                                       |

| ● | 285,373                                                                  
 shares of common stock reserved for future issuance under the 2022 Plan; |

| ● | 6,899,307                                                                                                                      
 shares of common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $4.50 per share; |

| ● | 688,165 shares of common stock issuable upon exercise of outstanding options at a weighted average exercise price of $2.78 per share; |

| ● | shares of common stock issuable upon the conversion of 76,480 shares of